The approval expands Lilly’s presence in the global obesity market and strengthens its position in the competition for oral GLP-1 treatments.

CHINA—Eli Lilly has secured approval for its oral obesity drug Foundayo (orforglipron) in China in November 2026, giving the pharmaceutical company an advantage over Novo Nordisk in the country’s emerging oral weight-loss market, according to Reuters.
The National Medical Products Administration (NMPA) approved Foundayo for weight management, making it the first oral glucagon-like peptide-1 receptor agonist (GLP-1RA) authorised for this indication in China.
The approval expands Lilly’s presence in the global obesity market and strengthens its position in the competition for oral GLP-1 treatments.
Lilly expands its obesity portfolio in China
Before Foundayo’s approval, China’s NMPA had authorised several injectable GLP-1-based treatments for weight management.
These include Lilly’s Zepbound (tirzepatide), Novo Nordisk’s Wegovy (semaglutide), Pfizer and Sciwind Biosciences’ Xianyida (ecnoglutide), and Innovent Biologics’ Xinermei (mazdutide).
Foundayo is now approved in four markets: the US, the UK, the UAE and China.
Its entry into China gives Lilly an advantage over Novo Nordisk, which is pursuing approval for its oral Wegovy formulation.
The NMPA accepted Novo’s marketing application earlier in 2026.
Chinese pharmaceutical companies are also targeting this market.
Huadong Medicine and Jiangsu Hengrui Pharmaceuticals are seeking regulatory approval for their respective oral obesity treatments, signalling growing domestic competition in the GLP-1 segment.
Oral GLP-1 market competition intensifies
Although Lilly secured the first oral GLP-1RA approval in China, Novo Nordisk entered the US market first with oral Wegovy.
This early commercial lead has helped establish Novo in the oral obesity treatment segment.
However, analysts at GlobalData forecast that oral Wegovy will generate higher sales than Foundayo in 2026.
They expect the competitive position to shift as Lilly expands its commercial reach and Foundayo gains market share.
GlobalData projects that Foundayo could generate more than US$21 billion in annual sales for Lilly by 2032, compared with approximately US$10 billion for oral Wegovy.
These forecasts highlight the commercial potential of oral obesity treatments and the importance of manufacturing capacity, market access and pricing as competition increases.
Obesity market developments reshape industry outlook
Foundayo’s approval comes as Lilly raises its 2026 financial outlook for the third time this year, following strong third-quarter performance from its tirzepatide portfolio.
Novo Nordisk, meanwhile, faces investor concerns about its future growth prospects following the reception of its five-year commercial strategy.
Beyond GLP-1 therapies, pharmaceutical companies are exploring additional approaches to cardiometabolic disease.
At the 2026 BIO-Europe conference, held in Cologne, Germany, from 9 to 11 November, industry experts identified amylin-based treatments and combination therapies involving GLP-1 receptor agonists as important areas for future development.
Researchers and drugmakers are increasingly focusing on treatments that improve tolerability, simplify administration and preserve muscle mass while supporting weight reduction.
Be the first to leave a comment